Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11611613 | 0.83 | TSHR (0.48) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL8764787 | 0.81 | L3MBTL1 (0.55) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL2059537 | 0.79 | KDM4E (0.71) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL982574 | 0.79 | L3MBTL1 (0.58) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL6771381 | 0.78 | L3MBTL1 (0.45) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL2948942 | 0.77 | KDM4E (0.42) | ALDH1A1KDM4EKMT2AMEN1ATM | |
| SCHEMBL10959076 | 0.77 | L3MBTL1 (0.52) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL10523979 | 0.77 | L3MBTL1 (0.52) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL20921192 | 0.77 | TSHR (0.43) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL8463126 | 0.77 | POLB (0.56) | L3MBTL1ALDH1A1KMT2AMEN1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108530297-B | Preparation method of 2-chloro-3-methylbenzoic acid and intermediate thereof | 联化科技股份有限公司 | 2021-09-24 | — | — | CN | claimed |
| EP-1622910-A1 | FUSED PYRIMIDINE DERIVATIVES WITH CRF ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-08 | — | — | EP | claimed |
| WO-2004099209-A1 | FUSED PYRIMIDINE DERIVATIVES WITH CRF ACTIVITY | F. HOFFMANN-LA-ROCHE AG (CH) | 2004-11-18 | — | — | WO | claimed |
| US-5874655-A | Process for the preparation of chlorinated aromatics | BAYER AKTIENGESELLSCHAFT (DE) | 1999-02-23 | — | — | US | claimed |
| EP-0694513-B1 | Process for preparing chlorinated aromatic compounds | BAYER AG (DE) | 1998-10-28 | — | — | EP | claimed |
| EP-0590259-B1 | Process for the preparation of halogenated aromatic compounds | BAYER AG (DE) | 1997-10-29 | — | — | EP | claimed |
| US-5306849-A | Process for the preparation of halogenated aromatics | BAYER AKTIENGESELLSCHAFT (DE) | 1994-04-26 | — | — | US | claimed |
| JP-7304697-A | — | — | None | — | — | JP | disclosed |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20190343842-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190343842-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| EP-3536323-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | Dana Farber Cancer Institute, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| US-4983616-A | Analgesics, cognition activators | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-01-08 | — | — | US | disclosed |
| US-4751173-A | USING QUATERNARY COMPOUND; RAPID, SELECTIVE | FUJI PHOTO FILM CO., LTD. (JP) | 1988-06-14 | — | — | US | disclosed |
| EP-0025659-B1 | PROCESSES FOR THE PRODUCTION OF 1,2,3-TRIHYDROXYPHENYL COMPOUNDS | FBC LIMITED (GB) | 1983-11-02 | — | — | EP | disclosed |
| US-4351968-A | Production of organic compounds | FBC LIMITED (GB) | 1982-09-28 | — | — | US | disclosed |
| EP-0025659-A2 | Processes for the production of 1,2,3-trihydroxyphenyl compounds | FBC LIMITED (GB) | 1981-03-25 | — | — | EP | disclosed |
| US-4069340-A | ARYLOXY DIMETHYL IMMONIUM CHLORIDES FROM DIMETHYL FORMAMIDE AND CORRESPONDING ARYL CHLOROFORMATES | HOOKER CHEMICALS & PLASTICS CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-3983178-A | Immonium salts and derivatives thereof | HOOKER CHEMICALS & PLASTICS CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343842-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK3, SIK2 | L3MBTL1 4559/4885SMN1; SMN2 4139/4885ALDH1A1 3380/4885 |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK3, SIK2 | L3MBTL1 4559/4885SMN1; SMN2 4139/4885ALDH1A1 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.